[Image courtesy of AP Technologies]
Singapore-based AP Technologies says the acquisition of the Dundalk, Ireland-based company establishes its first European operation. It also extends its catheter platform into the laser-processed metallic components used in next-generation minimally invasive devices.
The companies declined to disclose the terms of the deal.
“This acquisition marks the first step in extending our advanced catheter technologies platform, adding nitinol and precision laser processing to our vertically integrated catheter capabilities,” said Charles Tang, CEO of AP Technologies. “We are also thrilled to partner with David Gillen, founder of Blueacre Technology, whose engineering brilliance and innovation make him a tremendous addition to our team. Together, we are positioned to shape the future of minimally invasive device manufacturing.”
Blueacre offers nearly two decades of capability in laser micromachining and nitinol processing for the medical device industry. That includes femtosecond and picosecond laser cutting, laser welding, electropolishing and on-site rapid prototyping. AP Technologies adds that capability to its PTFE etched liners, FEP heat shrink tubing, braided and coiled shafts and finished catheter assembly.
AP Technologies believes the combination of offerings allows OEM partners to develop hybrid catheter and delivery system programs through a single supplier, with engineered precision across both polymeric and metallic processes.
Gillen will continue to lead the Dundalk operation as a member of AP Technologies’ leadership team. The Blueacre brand, Dundalk facility and active customer programs remain unaffected by the transaction.
“Blueacre Technology is delighted to become part of the AP Technologies global team,” said Gillen. “From our first meeting, we were impressed by the strategic vision of Charles Tang and senior management. AP Technologies has proven to be a highly successful and innovative global supplier to top-tier medtech companies. We are excited to bring nearly 20 years of experience in nitinol and advanced laser processing to our new joint team, as we build capability and develop vertical integration across the globe for the next generation of interventional devices.”
